
Mydayis
Dextroamphetamine Sulfate, Dextroamphetamine Saccharate, Amphetamine Aspartate Monohydrate, And Amphetamine Sulfate
- SKU
- 54092-468
- Mfr
- Takeda Pharmaceuticals America, Inc.
100 capsule, extended release in 1 bottle
$1,452.99
Price for one pack
Controlled medicine — prescription required. Upload your prescription at checkout or email it to us after ordering. We ship once a pharmacist has checked it and confirmed it with your prescriber. How it works
MYDAYIS is indicated for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) in patients 13 years and older [see Clinical Studies (14) ] . MYDAYIS is a central nervous system (CNS) stimulant indicated for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) in patients 13 years and older.
- Strength
- Dextroamphetamine Sulfate 3.125 mg/1, Dextroamphetamine Saccharate 3.125 mg/1, Amphetamine Aspartate Monohydrate 3.125 mg/1, Amphetamine Sulfate 3.125 mg/1
- Unit of measure
- Per 1 capsule
- Dosage form
- Capsule, Extended Release
- Route
- Oral
Pharmacologic class
- Central Nervous System StimulantEstablished class
- Central Nervous System StimulationPhysiologic effect
- Brand name
- Mydayis
- Generic name
- Dextroamphetamine Sulfate, Dextroamphetamine Saccharate, Amphetamine Aspartate Monohydrate, And Amphetamine Sulfate
- Manufacturer
- Takeda Pharmaceuticals America, Inc.
- Product NDC (SKU)
- 54092-468
- Active ingredients
- Dextroamphetamine Sulfate 3.125 mg/1, Dextroamphetamine Saccharate 3.125 mg/1, Amphetamine Aspartate Monohydrate 3.125 mg/1, Amphetamine Sulfate 3.125 mg/1
- Unit of measure
- Per 1 capsule
- Dosage form
- Capsule, Extended Release
- Route
- Oral
- DEA schedule
- CII
- Product type
- HUMAN PRESCRIPTION DRUG
- Marketing category
- NDA
- Application number
- NDA022063
- Marketed since
- June 20, 2017
- Label revised
- April 30, 2026
| Package NDC | Description |
|---|---|
| 54092-468-01 | 100 CAPSULE, EXTENDED RELEASE in 1 BOTTLE |
Reading this NDC
54092-468-01
- 01Labeler code
- Takeda Pharmaceuticals America, Inc.
- 02Product code
- Mydayis, capsule, extended release
- 03Package code
- 100 capsule, extended release in 1 bottle
Amphetamines are non-catecholamine sympathomimetic amines with CNS stimulant activity. The exact mode of therapeutic action in ADHD is not known.
Warning: Abuse, misuse, and addiction
MYDAYIS ® has a high potential for abuse and misuse, which can lead to the development of a substance use disorder, including addiction. Misuse and abuse of CNS stimulants, including MYDAYIS, can result in overdose and death [see Overdosage
], and this risk is increased with higher doses or unapproved methods of administration, such as snorting or injection. Before prescribing MYDAYIS, assess each patient’s risk for abuse, misuse, and addiction. Educate patients and their families about these risks, proper storage of the drug, and proper disposal of any unused drug. Throughout MYDAYIS treatment, reassess each patient’s risk of abuse, misuse, and addiction and frequently monitor for signs and symptoms of abuse, misuse, and addiction [see Warnings and Precautions
, Drug Abuse and Dependence
]. WARNING: ABUSE, MISUSE, AND ADDICTION See full prescribing information for complete boxed warning. MYDAYIS has a high potential for abuse and misuse, which can lead to the development of a substance use disorder, including addiction. Misuse and abuse of CNS stimulants, including MYDAYIS, can result in overdose and death: Before prescribing MYDAYIS, assess each patient’s risk for abuse, misuse, and addiction.
Educate patients and their families about these risks, proper storage of the drug, and proper disposal of any unused drug. Throughout treatment, reassess each patient’s risk and frequently monitor for signs and symptoms of abuse, misuse, and addiction.
MYDAYIS is indicated for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) in patients 13 years and older [see Clinical Studies
]. MYDAYIS is a central nervous system (CNS) stimulant indicated for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) in patients 13 years and older.
Limitations of Use. Pediatric patients 12 years and younger experienced higher plasma exposure than patients 13 years and older at the same dose and experienced higher rates of adverse reactions, mainly insomnia and decreased appetite.
Limitations of Use. Pediatric patients 12 years and younger experienced higher plasma exposure than patients 13 years and older at the same dose, and experienced higher rates of adverse reactions, mainly insomnia and decreased appetite [see Use in Specific Populations
].
Read before you order

ADHD · 2 min read
ADHD medication: stimulants vs non-stimulants
How methylphenidate, amphetamines, lisdexamfetamine, atomoxetine, guanfacine and viloxazine work, and how doctors choose between them.

ADHD · 2 min read
Living with ADHD medication side effects
Practical ways to handle reduced appetite, poor sleep and the afternoon crash on ADHD medicine, and when to call your doctor.

ADHD · 2 min read
ADHD medication in adults: what is different
Adult ADHD is often diagnosed late. Here is how treatment works for adults, including heart checks, interactions and alcohol.
More in ADHD
View all
Brand · Capsule
Adderall XR
Dextroamphetamine Sulfate 1.25 mg/1, Dextroamphetamine Saccharate 1.25 mg/1, Amphetamine Aspartate Monohydrate 1.25 mg/1, Amphetamine Sulfate 1.25 mg/1
- SKU
- 54092-381
- Mfr
- Takeda Pharmaceuticals America, Inc.
From $922.99Prescription required

Brand · Solution
Arynta
Lisdexamfetamine Dimesylate 10 mg/mL
- SKU
- 24338-019
- Mfr
- Azurity Pharmaceuticals, Inc.
From $1,100.00Prescription required

Generic · Capsule
Atomoxetine
Atomoxetine Hydrochloride 40 mg/1
- SKU
- 0904-6908
- Mfr
- Major Pharmaceuticals
From $18.99Min. 16 packs

Generic · Capsule
Atomoxetine
Atomoxetine Hydrochloride 40 mg/1
- SKU
- 71335-3033
- Mfr
- Bryant Ranch Prepack
From $18.99Min. 16 packs